Revolide is an anticancer drug that stimulates blood formation and is responsible for the development of blood cells (leukocytes, erythrocytes, platelets). The active ingredient of revolade is Eltrombopag. The glycoprotein hormone is the main signaling molecule that is involved in the management of megakaryocytopoiesis and is responsible for the production of platelets. Revolide combines with transmembrane receptors and creates a transmission line of information that recalls the reproduction of cancer cells and the formation of giant bone marrow cells from existing cells. Revolide affects platelets in a healthy body without increasing the aggregation under the influence of the nucleotide ADP and does not enhance the expression of P-selectin. Revolide does not prevent platelet aggregation under the function of ADP or fibrillar protein. The simultaneous intake of revolade with products that are rich in calcium (for example, cottage cheese, milk, kefir) significantly reduce the effectiveness of the drug. Absorption of revolade into the patient’s body occurs two to three hours after application. About 60% of revolade is excreted from the body with feces, and 32% when urinating.